(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Gynecologic Cancers
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)Small moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Gynecologic Cancers cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Indocyanine Green Istanbul University | Phase 4 | BB |
FULVESTRANT Atavistik Bio, Inc | Phase 2 | B |
Vesanoid Peking University People's Hospital | Phase 2 | CCC |
Romiplostim Peking University People's Hospital | Phase 2 | CCC |
Imgn151 AbbVie | Phase 2 | CCC |
Igf-Methotrexate Conjugate IGF Oncology, LLC | Phase 1 | CC |
Atv-1601 Atavistik Bio, Inc | Phase 1 | CC |
ROPIVACAINE Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | N/A | D |
Same molecule, other indications
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →